Article
Physiology
Brandon W. Lewis, Devine Jackson, Stephanie A. Amici, Joshua Walum, Manel Guessas, Sonia Guessas, Elise Coneglio, Akhila V. Boda, Mireia Guerau-de-Arellano, Mitchell H. Grayson, Rodney D. Britt
Summary: The increase in Th1 inflammation is associated with a decrease in corticosteroid sensitivity in severe asthma, but increased airway pathology and airway hyperresponsiveness still persist in the absence of STAT1, indicating corticosteroid insensitivity in structural airway cells is a process independent of STAT1.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2021)
Review
Allergy
Yan Xie, Peter W. Abel, Thomas B. Casale, Yaping Tu
Summary: Asthma can be classified into T2 and non-T2 types, with non-T2 asthma being more severe and often unresponsive to treatment. Recent studies suggest that non-T2 asthma is associated with T(H)17 cell immune responses, which may contribute to corticosteroid insensitivity in asthma.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Critical Care Medicine
Vidushi Sood, Linda Rogers, Sandhya Khurana
Summary: Oral corticosteroid (OCS) use in severe asthma is still common despite advances in treatment, but monoclonal antibodies have been developed to reduce OCS-treated exacerbations. Strategies for managing endocrine complications associated with OCS use include identifying OCS-dependent patients, optimizing OCS dose, tapering OCS based on asthma control criteria, assessing adrenal axis integrity, and managing corticosteroid-related comorbidities.
Article
Immunology
Jose M. Rodrigo-Munoz, Marta Gil-Martinez, Clara Lorente-Sorolla, Raquel Garcia-Latorre, Marcela Valverde-Monge, Santiago Quirce, Joaquin Sastre, Victoria del Pozo
Summary: MicroRNA miR-144-3p is identified as a potential diagnostic biomarker for severe asthma, as its expression is associated with the severity of the disease and corticosteroid treatment. It is increased in asthmatic lungs and serum, correlating with blood eosinophilia and genes involved in asthma pathophysiology. This miRNA shows promise as a novel biomarker for severe asthma previously treated with higher doses of corticosteroids.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Rahul S. Patil, Anita Kovacs-Kasa, Boris A. Gorshkov, David J. R. Fulton, Yunchao Su, Robert K. Batori, Alexander D. Verin
Summary: Vascular barrier dysfunction, characterized by increased permeability and inflammation of endothelial cells, plays a crucial role in acute lung injury, ARDS, sepsis, and COVID-19. Ser/Thr protein phosphatases (PPases), including PP1 and PP2A, are important regulators of endothelial barrier integrity and cytoskeletal remodeling. Understanding the role of PPases in EC barrier regulation can provide insights into the development of therapeutic strategies for these lung diseases.
Article
Allergy
Carlos Cardoso-Vigueros, Tobias von Blumenthal, Beate Rueckert, Arturo O. Rinaldi, Ge Tan, Anita Dreher, Urszula Radzikowska, Gunter Menz, Peter Schmid-Grendelmeier, Cezmi A. Akdis, Milena Sokolowska
Summary: This study aimed to determine the utility of leukocyte redistribution as a biomarker of disease heterogeneity in patients with severe asthma and as a bioindicator of potential corticosteroid resistance. Through clinical data analysis and flow cytometry, we identified two clusters of severe asthma patients with differences in cell frequencies, response to corticosteroids, and atopy status.
CLINICAL AND EXPERIMENTAL ALLERGY
(2022)
Article
Biochemistry & Molecular Biology
Yoshiki Kobayashi, Akira Kanda, Dan Van Bui, Yasutaka Yun, Linh Manh Nguyen, Hanh Hong Chu, Akitoshi Mitani, Kensuke Suzuki, Mikiya Asako, Hiroshi Iwai
Summary: Eosinophilic chronic rhinosinusitis (ECRS) is characterized by eosinophilic airway inflammation in both the upper and lower airways. Treatment with omalizumab for severe asthma coexistent with ECRS has shown promising results in reducing eosinophilic inflammation levels and restoring corticosteroid sensitivity.
Article
Plant Sciences
Xunlu Zhu, Guoxin Shen, Inosha Wijewardene, Yifan Cai, Nardana Esmaeili, Li Sun, Hong Zhang
Summary: Ethylene is a key plant hormone that regulates growth, development, and defense responses. The study demonstrates that PP2A-B'zeta positively regulates plant germination and seedling development, while also negatively regulating ethylene signaling pathway through interaction with CTR1. Further research is needed to fully understand the role of PP2A in ethylene responses.
PLANT PHYSIOLOGY AND BIOCHEMISTRY
(2021)
Article
Biochemistry & Molecular Biology
Ling Lei, Jun Feng, Gang Wu, Zhen Wei, Jian-Zhi Wang, Bin Zhang, Rong Liu, Fei Liu, Xiaochuan Wang, Hong-Lian Li
Summary: This study found that chronic hypoxia increased HIF-1 alpha, leading to tau hyperphosphorylation and cognitive impairment. HIF-1 alpha decreased PP2A activity by degrading LCMT1, resulting in increased tau phosphorylation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Allergy
Fahad H. Alahmadi, Brian Keevil, Lynn Elsey, Kate George, Robert Niven, Stephen J. Fowler
Summary: LC-MS/MS can reliably detect commonly used ICSs in the blood at least 8 hours after dosing, providing a measure of adherence in severe asthma patients. Lower blood levels were associated with higher exacerbation rates and poorer lung function.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Critical Care Medicine
Lawrence D. Sher, Michael E. Wechsler, Klaus F. Rabe, Jorge F. Maspero, Nadia Daizadeh, Xuezhou Mao, Benjamin Ortiz, Leda P. Mannent, Elizabeth Laws, Marcella Ruddy, Nami Pandit-Abid, Juby A. Jacob-Nara, Rebecca Gall, Paul J. Rowe, Yamo Deniz, David J. Lederer, Megan Hardin
Summary: This study found that in patients with severe OCS-dependent asthma, dupilumab treatment can maintain long-term reduction in OCS usage and demonstrate improvements in lung function and asthma control.
Article
Allergy
Charles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, Geoffrey Chupp, F. Eun-Hyung Lee, Jason Kihyuk Lee, Carlos Almonacid, Tobias Welte, Rafael Alfonso-Cristancho, Rupert W. Jakes, Aoife Maxwell, Robert G. Price, Peter Howarth
Summary: This 1-year analysis demonstrates that real-world mepolizumab treatment is clinically effective in patients with severe asthma, providing disease control while reducing the need for mOCS and SCS bursts.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Article
Immunology
Hariharan Subramanian, Tanwir Hashem, Devika Bahal, Ananth K. Kammala, Kanedra Thaxton, Rupali Das
Summary: Asthma prevalence has been on the rise and is considered a common chronic disorder. Some patients develop severe asthma that is not controlled by standard therapies, and inhibiting JAK signaling pathways shows promise in alleviating symptoms and inflammation associated with severe asthma.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Kian Fan Chung, Piers Dixey, Hisham Abubakar-Waziri, Pankaj Bhavsar, Pujan H. Patel, Sujuan Guo, Yang Ji
Summary: Severe asthma refers to asthma that requires high dose inhaled corticosteroids and additional controllers to prevent uncontrolled symptoms. Phenotyping of severe asthma has identified different inflammatory profiles, such as Type-2 and non-Type-2, which may require different treatment approaches. Targeted antibody treatments are available for Type-2 inflammatory phenotypes, but currently there are no targeted treatments for non-Type-2 phenotypes. Molecular phenotyping is seen as the future of refining asthma treatment for precision medicine.
CHINESE MEDICAL JOURNAL
(2022)
Article
Allergy
Charles Pilette, Giorgio Walter Canonica, Rekha Chaudhuri, Geoffrey Chupp, F. Eun-Hyung Lee, Jason Kihyuk Lee, Carlos Almonacid, Tobias Welte, Rafael Alfonso-Cristancho, Rupert W. Jakes, Aoife Maxwell, Robert G. Price, Peter Howarth
Summary: The study demonstrates that mepolizumab treatment in patients with severe asthma can effectively reduce oral corticosteroid dosage and decrease the rate of clinically significant exacerbations.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Letter
Respiratory System
Sophia Havaki, Konstantinos Evangelou, Koralia Paschalaki, Russell Petty, Peter J. Barnes, Vassilis G. Gorgoulis
EUROPEAN RESPIRATORY JOURNAL
(2022)
Editorial Material
Pharmacology & Pharmacy
Peter J. Barnes
Summary: A recent study reveals the role of CCR1 in eosinophilic inflammation and the increased levels of its ligand CCL15 in asthmatic eosinophils. Another study demonstrates that N-truncated forms of CCL15 generated by tissue proteases induce biased CCR1 signaling. These findings may contribute to the development of more effective oral therapy for asthma by producing CCR antagonists.
TRENDS IN PHARMACOLOGICAL SCIENCES
(2022)
Article
Critical Care Medicine
Jonathan R. Baker, Mahdi Mahdi, Dan V. Nicolau, Sanjay Ramakrishnan, Peter J. Barnes, Jodie L. Simpson, Steven P. Cass, Richard E. K. Russell, Louise E. Donnelly, Mona Bafadhel
Summary: This study aimed to investigate the mechanism of action of inhaled corticosteroid budesonide in the treatment of early COVID-19. The study found that early COVID-19 disease exhibited enhanced inflammatory airway response and increased anti-viral and T-helper 1/2 (Th1/2) inflammatory response, while budesonide treatment reduced inflammation and improved T-cell response.
LANCET RESPIRATORY MEDICINE
(2022)
Review
Allergy
P. N. Richard Dekhuijzen, Mark L. Levy, Chris J. Corrigan, Ruth M. Hadfield, Nicolas Roche, Omar S. Usmani, Peter J. Barnes, Jane E. Scullion, Federico Lavorini, Lorenzo Corbetta, Janwillem W. H. Kocks, Borja G. Cosio, Roland Buhl, Soren E. Pedersen
Summary: This study reveals a concerning lack of checking and correcting inhaler technique in RCTs for asthma and COPD, which may impact the study conclusions. It is recommended to mandate the use of a standardized checklist in RCT protocols and ensure that all published RCTs report checking and correcting inhaler technique before enrollment.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2022)
Review
Allergy
Ian D. Pavord, Peter J. Barnes, Catherine Lemiere, Peter G. Gibson
Summary: Optimizing asthma diagnosis is crucial for reducing the burden of asthma globally. A compound diagnostic approach and label are now required due to the complexity and heterogeneity of different forms of asthma. By recognizing typical symptoms and abnormal physiology, asthma can be identified, and further features such as eosinophilic or type 2 inflammation can be used to give a compound diagnostic label of eosinophilic asthma, which provides important information about future exacerbation risk and treatment responsiveness. Implementing treatable traits and using targeted assessment allows for a specific treatment plan based on a pragmatic and iterative process. (c) 2022 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology (J Allergy Clin Immunol Pract 2023;11:1-8)
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Critical Care Medicine
Mario Cazzola, Paola Rogliani, Peter J. Barnes, Francesco Blasi, Bartolome Celli, Nicola A. Hanania, Fernando J. Martinez, Bruce E. Miller, Marc Miravitlles, Clive P. Page, Ruth Tal-Singer, Maria Gabriella Matera
Summary: This paper reviews the advances in chronic obstructive pulmonary disease research and highlights the need to update the original report. New measurement tools and evaluation methods are proposed to facilitate the development of personalized treatment and precision medicine.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2023)
Article
Respiratory System
Alvar Agusti, Bartolome R. Celli, Gerard J. Criner, David Halpin, Antonio Anzueto, Peter Barnes, Jean Bourbeau, MeiLan K. Han, Fernando J. Martinez, Maria Montes de Oca, Kevin Mortimer, Alberto Papi, Ian Pavord, Nicolas Roche, Sundeep Salvi, Don D. Sin, Dave Singh, Robert Stockley, Victorina Lopez Varela, Jadwiga A. Wedzicha, Claus F. Vogelmeier
ARCHIVOS DE BRONCONEUMOLOGIA
(2023)
Article
Respiratory System
Don D. Sin, Dany Doiron, Alvar Agusti, Antonio Anzueto, Peter J. Barnes, Bartolome R. Celli, Gerard J. Criner, David Halpin, MeiLan K. Han, Fernando J. Martinez, Maria Montes de Oca, Alberto Papi, Ian Pavord, Nicolas Roche, Dave Singh, Robert Stockley, Victorina Lopez Varlera, Jadwiga Wedzicha, Claus Vogelmeier, Jean Bourbeau, GOLD Sci Comm
Summary: Exposure to air pollution is a major contributor to COPD worldwide. Strong public health policies should be implemented to reduce ambient air pollution, accompanied by public warning systems and advisories to alert patients when air pollution levels exceed acceptable thresholds. Patients should consider using air cleaners and filters when household particulate content exceeds acceptable levels.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Respiratory System
Alvar Agusti, Bartolome R. Celli, Gerard J. Criner, David Halpin, Antonio Anzueto, Peter Barnes, Jean Bourbeau, MeiLan K. Han, Fernando J. Martinez, Maria Montes de Oca, Kevin Mortimer, Alberto Papi, Ian Pavord, Nicolas Roche, Sundeep Salvi, Don D. Sin, Dave Singh, Robert Stockley, M. Victorina Lopez Varela, Jadwiga A. Wedzicha, Claus F. Vogelmeier
EUROPEAN RESPIRATORY JOURNAL
(2023)
Review
Biochemistry & Molecular Biology
Suhana Ahmad, Norhayati Mohd Noor, E. A. R. Engku Nur Syafirah, Ahmad Adebayo Irekeola, Rafidah Hanim Shueb, Yean Yean Chan, Peter J. Barnes, Rohimah Mohamud
Summary: This study evaluated the efficacy and safety of anti-tumor necrosis factor (TNF) as a supplementary therapy for patients with severe asthma. The results showed that anti-TNF treatment improved asthma control, but there was limited evidence for improvement in lung function and reduction of asthma exacerbation. Therefore, prescribing anti-TNF in adults with severe asthma is unlikely.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
(2023)
Article
Biology
Vanessa Ho, Jonathan R. Baker, Keith R. Willison, Peter J. Barnes, Louise E. Donnelly, David R. Klug
Summary: An amplification-free sandwich hybridisation assay using a microfluidic platform is developed to detect single miRNA molecules in single cells. The absolute quantification of miRNAs at a single cell level is achieved and validated using real-time qPCR. The sensitivity of the assay is demonstrated by quantifying single miRNA molecules in nasal fluid, showing its potential utility in clinical studies.
COMMUNICATIONS BIOLOGY
(2023)
Review
Primary Health Care
Jennifer K. Quint, Amnon Ariel, Peter J. Barnes
Summary: Inhaled corticosteroids (ICS) are commonly used for asthma treatment, but their role in chronic obstructive pulmonary disease (COPD) is still a topic of debate. Recent trials have shown that ICS combined with dual bronchodilator therapy can significantly reduce exacerbations in COPD patients. However, the suggestion of a mortality benefit associated with ICS in these trials has been rejected. Observational evidence suggests that dual bronchodilation is associated with better outcomes than triple therapy in a broad population of COPD patients. It is recommended that ICS be reserved for patients with frequent or severe exacerbations and high blood eosinophils or those with concomitant asthma.
NPJ PRIMARY CARE RESPIRATORY MEDICINE
(2023)
Letter
Biochemistry & Molecular Biology
Hugo C. J. Ombredane, Peter S. Fenwick, Peter J. Barnes, Mona Bafadhel, Kazuhiro Ito, Louise E. Donnelly, Jonathan R. Baker
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2023)
Meeting Abstract
Respiratory System
J. Devulder, J. R. Baker, L. Odqvist, L. E. Donnelly, P. J. Barnes
EUROPEAN RESPIRATORY JOURNAL
(2022)
Meeting Abstract
Respiratory System
V. Ho, J. R. Baker, K. R. Willison, D. R. Klug, P. J. Barnes, L. E. Donnelly
EUROPEAN RESPIRATORY JOURNAL
(2022)